Arkin Bio Ventures Limited Partnership - Net Worth and Insider Trading
Arkin Bio Ventures Limited Partnership Net Worth
The estimated net worth of Arkin Bio Ventures Limited Partnership is at least $100 Million dollars as of 2024-06-14. Arkin Bio Ventures Limited Partnership is the 10% Owner of Keros Therapeutics Inc and owns about 2,013,102 shares of Keros Therapeutics Inc (KROS) stock worth over $100 Million. Details can be seen in Arkin Bio Ventures Limited Partnership's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Arkin Bio Ventures Limited Partnership has not made any transactions after 2020-04-13 and currently still holds the listed stock(s).
Transaction Summary of Arkin Bio Ventures Limited Partnership
Arkin Bio Ventures Limited Partnership Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Arkin Bio Ventures Limited Partnership owns 1 companies in total, including Keros Therapeutics Inc (KROS) .
Insider Ownership Summary of Arkin Bio Ventures Limited Partnership
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| KROS | Keros Therapeutics Inc | 2020-04-13 | 10 percent owner |
Arkin Bio Ventures Limited Partnership Latest Holdings Summary
Arkin Bio Ventures Limited Partnership currently owns a total of 1 stock. Arkin Bio Ventures Limited Partnership owns 2,013,102 shares of Keros Therapeutics Inc (KROS) as of April 13, 2020, with a value of $100 Million.
Latest Holdings of Arkin Bio Ventures Limited Partnership
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| KROS | Keros Therapeutics Inc | 2020-04-13 | 2,013,102 | 49.50 | 99,648,549 |
Holding Weightings of Arkin Bio Ventures Limited Partnership
Arkin Bio Ventures Limited Partnership Form 4 Trading Tracker
According to the SEC Form 4 filings, Arkin Bio Ventures Limited Partnership has made a total of 1 transactions in Keros Therapeutics Inc (KROS) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Keros Therapeutics Inc is the acquisition of 120,000 shares on April 13, 2020, which cost Arkin Bio Ventures Limited Partnership around $2 Million.
Insider Trading History of Arkin Bio Ventures Limited Partnership
- 1
Arkin Bio Ventures Limited Partnership Trading Performance
GuruFocus tracks the stock performance after each of Arkin Bio Ventures Limited Partnership's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Arkin Bio Ventures Limited Partnership is 32.59%. GuruFocus also compares Arkin Bio Ventures Limited Partnership's trading performance to market benchmark return within the same time period. The performance of stocks bought by Arkin Bio Ventures Limited Partnership within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Arkin Bio Ventures Limited Partnership's insider trading performs compared to the benchmark.
Performance of Arkin Bio Ventures Limited Partnership
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 23.76 | | | | | |
| Relative Return to S&P 500(%) | 21.65 | | | | | |
Arkin Bio Ventures Limited Partnership Ownership Network
Arkin Bio Ventures Limited Partnership Owned Company Details
What does Keros Therapeutics Inc do?
Who are the key executives at Keros Therapeutics Inc?
Arkin Bio Ventures Limited Partnership is the 10 percent owner of Keros Therapeutics Inc. Other key executives at Keros Therapeutics Inc include Chief Financial Officer Keith Regnante , Chief Scientific Officer Jennifer Lachey , and Chief Operating Officer Christopher Rovaldi .
Keros Therapeutics Inc (KROS) Insider Trades Summary
Over the past 18 months, Arkin Bio Ventures Limited Partnership made no insider transaction in Keros Therapeutics Inc (KROS). Other recent insider transactions involving Keros Therapeutics Inc (KROS) include a net sale of 80,000 shares made by Keith Regnante ,
In summary, during the past 3 months, insiders sold 0 shares of Keros Therapeutics Inc (KROS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 80,000 shares of Keros Therapeutics Inc (KROS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 80,000 shares.
Keros Therapeutics Inc (KROS)'s detailed insider trading history can be found in Insider Trading Tracker table.
Keros Therapeutics Inc Insider Transactions
Arkin Bio Ventures Limited Partnership Mailing Address
Above is the net worth, insider trading, and ownership report for Arkin Bio Ventures Limited Partnership. You might contact Arkin Bio Ventures Limited Partnership via mailing address: 6 Hachoshlim Street, Herzliya Pituach L3 4672406.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
